Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
After an earlier-than-expected FDA green light, Shionogi is rolling out COVID-19 antiviral Xocova with a tagline urging consumers to “make the call” on the pill after exposure. | Shionogi's “Got the Call, Make the Call” campaign for COVID antiviral Xocova kicks off with a TV ad depicting a mother getting a call from her COVID-infected son.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a…

Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in…

The FDA on Monday approved the first medication for COVID-19 prevention that people can take after they have been exposed to…

Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following…

Drug arrives years after pandemic’s peak, but could still offer critical protection to vulnerable populations.

Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio…